# Host Transcriptomic, Microbiome, and Pathogen Genomic Signatures Predictive of Treatment Response and Relapse in Multidrug-Resistant Tuberculosis Patients

**AI-Generated Research Manuscript - DEMONSTRATION ONLY**

*This is a demonstration manuscript generated by AI to showcase the capability of automated scientific writing and data analysis. It is NOT a real research study, has NOT been published anywhere, and does NOT contain actual patient data or results from real experiments. All data, methods, and findings are simulated for illustrative purposes only.*

---

## **Important Ethical and Legal Disclaimers**

⚠️ **This manuscript is generated by artificial intelligence for demonstration purposes only.**

- **Not Published:** This work has never been submitted or published in any scientific journal or conference
- **No Authors:** No real researchers are associated with this work
- **Simulated Data:** All patient data, experimental results, and statistical findings are artificially generated
- **No Real Research:** No actual patient data was collected, no laboratory experiments were performed
- **AI Demonstration:** This document showcases automated scientific writing capabilities
- **Not Citable:** Do not use as reference material in real research papers

---

## **Abstract**

**Background:** Multidrug-resistant tuberculosis (MDR-TB) represents a global health crisis with treatment success rates below 50% and high relapse risk. Current predictive tools fail to identify patients most likely to benefit from intensive therapy or experience relapse.

**Objective:** To identify multi-omics signatures predictive of treatment response and relapse using integrated host transcriptomics, microbiome profiling, and Mycobacterium tuberculosis genomic analysis.

**Methods:** We conducted a comprehensive multi-omics analysis of 300 MDR-TB patients from five international cohorts (**simulated data - not from real patients**). Host RNA-seq was analyzed using DESeq2 with false discovery control. Microbiome data was processed via nf-core/ampliseq for taxonomic profiling and diversity assessment. MTB WGS was analyzed for drug resistance mutations and compensatory mechanisms. Integration utilized DIABLO sparse multi-block PLS-DA and machine learning ensemble methods.

**Results:** We identified a 147-feature signature (AUC = 0.87, 95% CI: 0.82-0.92) integrating host immune dysregulation, microbiome dysbiosis, and bacterial fitness markers. Key biomarkers included:

- **Host Response:** IFN-γ pathway upregulation (adj. p-value < 0.001), TNF-α signaling (adj. p-value = 0.002), and metabolic reprogramming signatures
- **Microbiome:** Enrichment of *Prevotella copri* and *Bacteroides fragilis* (p-value < 0.01), depletion of *Faecalibacterium prausnitzii* (p-value = 0.003)
- **Pathogen:** Ribosomal mutations (rpoB A94V, adj. p-value = 0.045) and compensatory mutations in respiratory chain genes (adj. p-value = 0.018)

The signature demonstrated 89% sensitivity (95% CI: 84-94%) and 82% specificity (95% CI: 76-88%) for predicting 6-month culture conversion, with superior performance compared to current clinical tools (p-value < 0.001).

**Conclusions:** Multi-omics integration identifies clinically-actionable biomarkers for MDR-TB treatment optimization. The signature enables precision medicine approaches for MDR-TB management, potentially improving treatment allocation and reducing healthcare costs by 35% through targeted intervention.

**Funding:** NIH-NIAID Global TB Research Program (grant #TB-2024-001); Wellcome Trust Human Microbiome Initiative (grant #HMI-2023-015); European Commission's Horizon Europe TB Programme (grant #EH-2024-TB-012)

**Keywords:** multidrug-resistant tuberculosis, multi-omics, biomarkers, precision medicine, machine learning, treatment outcomes

---

## **Introduction**

### **Global Tuberculosis Burden**
Tuberculosis (TB) remains the world's deadliest infectious disease, causing 1.4 million deaths annually¹. The emergence of multidrug-resistant (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) has compounded this crisis, with treatment success rates of only 49%² and prohibitive costs exceeding $10,000-20,000 per patient³.

### **Clinical Challenge: Treatment Response Prediction**
Current WHO guidelines recommend 18-24 months of intensive therapy for MDR-TB patients⁴. However, outcomes are highly variable: approximately 30-50% experience treatment failure due to toxicity, inadequate response, or non-adherence⁵. Moreover, 10-20% of treatment "successes" experience relapse within 12 months⁶.

The inability to identify patients likely to benefit from intensified therapy or predict relapse risk represents a major clinical gap. This uncertainty results in suboptimal resource allocation and increased patient suffering through unnecessary prolonged treatment or undetected relapse.

### **Emerging Paradigm: Multi-Omics Biomarkers**
Recent advances in omics technologies offer new possibilities for understanding MDR-TB pathobiology and predicting treatment outcomes:

- **Host transcriptomics** reveal immune dysregulation and drug response mechanisms⁷,⁸
- **Gut microbiome** influences drug metabolism and immune modulation⁹,¹⁰
- **Mycobacterium tuberculosis genomics** provides insights into bacterial fitness and resistance⁻¹¹

### **Research Question**
**Which host transcriptomic, microbiome, and pathogen genomic signatures are predictive of treatment response and relapse in multidrug-resistant tuberculosis patients?**

---

## **Methods**

### **Study Design and Patient Recruitment**
We conducted a multicenter prospective cohort study including 300 MDR-TB patients from five international sites:

- Cape Town, South Africa (n=80)
- Lima, Peru (n=60)
- Mumbai, India (n=80)
- Phnom Penh, Cambodia (n=50)
- Rio de Janeiro, Brazil (n=30)

Inclusion criteria:
- Confirmed MDR-TB (resistance to rifampicin + isoniazid)
- Age ≥ 18 years
- Willingness to provide biological samples
- No co-infection with HIV or active malignancy

### **Clinical Assessment**
Treatment outcomes were assessed according to WHO criteria:
- **Cure**: Negative culture at treatment completion and one year follow-up
- **Treatment completion**: Completed therapy with no relapse evidence
- **Failure**: Positive culture after 24 months or >20% positive cultures (months 4-5 therapy)
- **Died**: Death during treatment

Relapse was defined as positive culture after cure/treatment completion (6-24 months follow-up).

### **Omics Data Collection and Processing**

#### **Host Transcriptomics (RNA-seq)**
- Blood samples collected pre-treatment and weeks 2, 4, 8 during treatment
- PAXgene tubes stabilized mRNA for 24-hour transport from field sites
- Sequencing on Illumina NovaSeq 6000 (paired-end 75bp reads)
- Processing via nf-core/rnaseq pipeline (STAR alignment, featureCounts quantification)
- Quality control: FastQC, MultiQC reporting
- Differential expression analysis: DESeq2 with Benjamini-Hochberg FDR correction

#### **Gut Microbiome Profiling (16S rRNA)**
- Stool samples collected at baseline and months 1, 2, 4
- DNA extraction: MoBio PowerSoil kit
- Library preparation: Illumina 16S Metagenomics Sequencing
- Sequencing: 2×250 bp paired-end reads targeting V3-V4 regions
- Processing: nf-core/ampliseq pipeline with DADA2 denoising
- Taxonomy assignment: SILVA database, confidence threshold >80%

#### **MTB Whole Genome Sequencing**
- Sputum DNA extraction from positive cultures
- Library preparation: Illumina TruSeq DNA PCR-Free
- Sequencing: 75x coverage minimum
- Analysis: TB-Profiler v4.1 for drug resistance profiling¹²
- Custom pipeline for compensatory mutations and bacterial fitness markers

### **Data Integration and Statistical Analysis**

#### **Multi-Omics Matrix Construction**
- Clinical metadata harmonized across cohorts
- Feature selection: Variance threshold >0.95, correlation >0.8 filtered
- Missing value imputation: KNN-imputation (k=5)
- Normalization: CLR transform (microbiome), RLOG (transcriptomics), Z-score standardization

#### **Machine Learning Pipeline**
- **DIABLO Integration**: Sparse multi-block PLS-DA for multi-omics fusion¹³
- **Feature Selection**: Univariate filtering (p-value <0.05) + LASSO+L2 regularization
- **Model Development**:
  - Random Forest (500 trees)
  - XGBoost with hyperparameter optimization
  - Support Vector Machines (RBF kernel)
  - Ensemble stacking for final prediction
- **Cross-Validation**: 5-fold nested CV with external validation set (20%)

#### **Performance Metrics**
- Primary: AUC-ROC, sensitivity, specificity for culture conversion at 6 months
- Secondary: Relapse prediction at 12 months, treatment success at 24 months
- Clinical utility: Decision curve analysis for net benefit calculation

#### **Validation Approach**
- **Internal validation**: 5-fold cross-validation stratified by site
- **External validation**: Held-out test set (20% of cohort)
- **Robustness testing**: Subgroup analysis by site, treatment regimen, baseline severity

### **Ethical Considerations**
Protocols approved by local ethics committees (approval numbers: SA-2023-MDR-001, PE-2023-TB-015, IN-2023-R-neg-303, etc.). All patients provided written informed consent. Data de-identified and processed according to HIPAA standards.

---

## **Results**

### **Patient Demographics and Clinical Outcomes**
Table 1 demonstrates participant characteristics and outcomes:

| **Characteristic** | **Overall (n=300)** | **Cure (n=98, 33%)** | **Completion (n=79, 26%)** | **Failure (n=65, 22%)** | **Death (n=58, 19%)** |
|---------------------|---------------------|----------------------|--------------------------|-----------------------|---------------------|
| **Age, median (IQR)** | 35 (28-47) | 38 (31-46) | 33 (27-42) | 36 (29-49) | 42 (37-52) |
| **Male Sex, %** | 68% | 71% | 65% | 69% | 72% |
| **Cavities, %** | 76% | 71% | 67% | 82% | 90% |
| **HIV co-infection, %** | 15% | 9% | 10% | 22% | 26% |
| **Prior TB treatment, %** | 53% | 48% | 51% | 58% | 60% |
| **BMI < 18.5, %** | 31% | 28% | 25% | 35% | 45% |

**Table 1:** Patient characteristics by treatment outcome

### **Host Transcriptomic Signatures**

Differential expression analysis identified robust immune dysregulation patterns (Figure 1):

**Up-regulated Pathways:**
- Interferon-γ signaling pathway (28 genes, adj. p-value < 2.2×10⁻¹⁶)
- TNF-α/NF-κB signaling (adj. p-value = 3.4×10⁻¹²)
- Antigen processing and presentation (adj. p-value = 1.1×10⁻¹⁰)

**Down-regulated Pathways:**
- Metabolic reprogramming (TCA cycle, adj. p-value = 5.6×10⁻⁸)
- Oxidative phosphorylation (adj. p-value = 1.8×10⁻⁶)
- Lipid metabolism pathways (adj. p-value = 4.2×10⁻⁵)

Key predictive genes included:
- **IFNG** (log₂FC = 2.31, adj. p-value = 8.7×10⁻¹⁵)
- **TNF** (log₂FC = 1.94, adj. p-value = 2.3×10⁻¹²)
- **IL6** (log₂FC = 1.67, adj. p-value = 4.8×10⁻¹⁰)
- **LTA4H** (log₂FC = -1.78, adj. p-value = 1.2×10⁻⁸) (responsible for compound 12 metabolism)

### **Microbiome Dysbiosis Patterns**

16S rRNA profiling revealed significant gut microbiome alterations (Figure 2):

**Alpha Diversity Metrics:**
- Shannon diversity significantly reduced in treatment failures (p-value = 0.002)
- Simpson index negatively correlated with MDR-TB severity (Spearman ρ = -0.34, p-value = 0.001)

**Taxonomic Shifts:**
- **Increased taxa:** *Prevotella copri* (p-value = 0.004), *Bacteroides fragilis* (p-value = 0.007)
- **Decreased taxa:** *Faecalibacterium prausnitzii* (p-value = 0.003), *Ruminococcaceae* spp. (p-value = 0.012)

**Functional Implications:**
Microbiome dysbiosis associated with impaired drug metabolism and immune modulation pathways.

### **Mycobacterium tuberculosis Genomic Signatures**

WGS analysis revealed bacterial fitness markers (Figure 3):

**Drug Resistance Mutations:**
- **rpoB S450L**: 62% of cohort (adj. p-value = 0.015 vs. resolution)
- **katG S315T**: 58% (adj. p-value = 0.022 vs. resolution)
- **inhA promoter -15C→T**: 34% (adj. p-value = 0.089 vs. resolution)

**Compensatory Mutations:**
- **RpsL mutations** associated with better treatment outcomes (adj. p-value = 0.018)
- **Oxidative stress response genes** (SodA, ThkA) compensatory mutations linked to treatment success

**Bacterial Fitness Score:**
Composite score incorporating:
- Replicative fitness alleles
- Resistance burden assessment
- Compensatory mechanisms

### **Integrated Multi-Omics Signature Performance**

#### **Model Development and Feature Selection**
- **DIABLO analysis** identified 147 informative features (12% recurrence)
- Feature breakdown: 89 transcriptomic, 41 microbiome, 17 genomic

#### **Primary Outcome: 6-Month Culture Conversion**
Signature performance:
- **AUC**: 0.87 (95% CI: 0.82-0.92)
- **Sensitivity**: 89% (95% CI: 84-94%)
- **Specificity**: 82% (95% CI: 76-88%)
- **PPV**: 85% (95% CI: 80-91%)
- **NPV**: 87% (95% CI: 81-92%)

#### **Secondary Outcomes**
- **24-Month Success Rate**: AUC 0.91 (95% CI: 0.86-0.95)
- **Relapse Prediction** (12-month): AUC 0.79 (95% CI: 0.73-0.85)

#### **Clinical Utility Assessment**
**Decision Curve Analysis:**
Net benefit analysis demonstrated superiority over current clinical approaches:
- Current approach: Net benefit = 0.23
- Multi-omics signature: Net benefit = 0.34
- Threshold probability range: 10-35% (p-value < 0.001)

### **Subgroup and Validation Analyses**

#### **Cross-Site Validation**
Performance metrics consistent across international cohorts:
- Africa (n=80): AUC 0.85
- Asia (n=130): AUC 0.89
- Americas (n=90): AUC 0.86

#### **Treatment Regimen Stratification**
Superior performance in patients receiving longer regimens:
- **6-month intensive regimen**: AUC 0.90
- **Standard regimen**: AUC 0.84
- Interaction p-value = 0.048

#### **Traditional Predictors**
When adjusted for traditional clinical factors, multi-omics signature remained independent predictor:
- Adjusted OR: 4.2 (95% CI: 2.8-6.3, p-value < 0.001)

---

## **Discussion**

### **Main Findings**
This multi-omics analysis represents the most comprehensive effort to date identifying predictive biomarkers for MDR-TB treatment outcomes. Our integrated 147-feature signature significantly outperformed current clinical approaches, providing a pathway toward precision medicine in MDR-TB management.

### **Biological Interpretations**

#### **Host Immune Dysregulation**
The prominence of IFN-γ pathway upregulation suggests that persistent immune activation contributes to poor treatment outcomes. This aligns with recent immunoproteomic studies¹⁴ demonstrating that excessive inflammation impairs antibiotic efficacy through hepatic drug metabolism interference.

#### **Gut Microbiome Contributions**
Gut microbiome dysbiosis, particularly depletion of *Faecalibacterium prausnitzii*, indicates loss of beneficial bacteria producing short-chain fatty acids that modulate immune function. This finding supports emerging evidence that microbiome composition influences TB treatment response¹⁵.

#### **Pathogen Fitness Markers**
Compensatory mutations in fitness-related genes (rpsL, Rv0678) suggest that bacterial adaptive responses to antibiotic stress predict treatment outcomes. This provides mechanistic insight into why certain resistance mutations are associated with worse prognosis.

### **Clinical Implications**
Our signature could revolutionize MDR-TB management by:
- Identifying patients requiring intensified therapy (top 35%)
- De-escalating unnecessary treatment for low-risk patients
- Improving resource allocation in resource-limited settings
- Reducing relapse rates through targeted monitoring

### **Strengths and Limitations**

#### **Strengths**
- Largest multi-omics MDR-TB cohort to date
- Multi-site international validation
- Rigorous statistical methodology
- Clinical utility assessment with decision analysis

#### **Limitations**
- Long-term longitudinal sampling not captured
- Microbiome perturbation by antibiotic treatment
- Generalizability to HIV-co-infected populations limited
- Cost considerations for omics implementation

### **Future Directions**
- Integration with point-of-care molecular diagnostics
- Serial monitoring during treatment to identify non-responders
- Expansion to XDR-TB and pre-MDR cases
- Cost-effectiveness analysis for clinical implementation

---

## **Conclusion**

This comprehensive multi-omics analysis identifies robust biomarkers combining host immune status, gut microbiome composition, and bacterial genomic fitness that predict MDR-TB treatment response and relapse risk. The 147-feature signature demonstrates excellent predictive performance and clinical utility, providing a foundation for precision medicine approaches in MDR-TB management.

Implementation of these biomarkers could significantly improve MDR-TB treatment outcomes by enabling targeted therapeutic interventions, reducing unnecessary toxicity, and optimizing resource allocation in global tuberculosis control efforts.

---

## **References**

¹ World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023.

² Sloan DJ, Mwandumba HC. Multidrug-resistant tuberculosis treatment wastage and outcomes in Ghana. *Int J Infect Dis.* 2019;88:110-115.

³ Pooran A, Pieterson E, Davids M, et al. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? *PLoS One.* 2013;8(1):e54587.

⁴ World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: WHO; 2010.

⁵ Van-Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. *Am J Respir Crit Care Med.* 2010;182(5):684-692.

⁶ Rodrigues M, Materia S, Sacchi F, et al. Relapse in multidrug-resistant tuberculosis disease: where do we stand? A systematic review and meta-analysis. *Eur Respir J.* 2022;60:2200844.

⁷ Thompson EG, Du Y, Malherbe ST, et al. Host blood RNA signatures predict the outcome of tuberculosis treatment. *Tuberculosis (Edinb).* 2017;107:48-58.

⁸ Cliff JM, Cho J-ES, Lee JS, et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the host immune response. *J Infect Dis.* 2013;207(1):18-29.

⁹ Chen Y, Mi W, Ma R, et al. The composition and function of the pulmonary microbiome in tuberculosis. *Tuberculosis (Edinb).* 2019;115:1-7.

¹⁰ Bai L, Deng Y, Zweig S, et al. The gut microbiome and tuberculosis treatment outcomes in the UK. *Microbiome.* 2022;10(1):189.

¹¹ Reynolds LB, Anh PH, Kalonji E, et al. Relative abundance of cell wall-associated proteins in *Mycobacterium tuberculosis* clinical isolates with mutations in the *embB* locus. *J Bacteriol.* 2014;196(7):1423-1431.

¹² Coll F, Preston M, Guerra-Assunção JA, et al. Rapid detection of *Mycobacterium tuberculosis* whole genome sequencing and drug resistance from sputum by nanopore sequencing. *Genome Med.* 2019;11:47.

¹³ Singh A, Shannon CP, Gautier B, et al. DIABLO: an integrative approach for identifying key molecular drivers from multi-omics assays. *Bioinformatics.* 2019;35(17):3055-3062.

¹⁴ Coppens FEJ, van den Mosselaar B, Bouwman FGF, et al. The leukocyte transcriptome as predictor of drug resistance. *Clin Infect Dis.* 2022;75(1):77-85.

¹⁵ Cheung MK, Lam WO, Fung WY, et al. Altered gut microbiota in association with symptom severity in schizophrenia. *NPC Psychiatry.* 2019;5:16.

---

## **Supplementary Materials**

### **Appendix A: Full Statistical Results**

#### **Transcriptomic Feature Importance**
| **Gene** | **log₂FC** | **Adjusted P-value** | **AUC Contribution** |
|----------|------------|---------------------|-------------------|
| IFNG | 2.31 | 8.7×10⁻¹⁵ | 0.145 |
| TNF | 1.94 | 2.3×10⁻¹² | 0.132 |
| CD274 | 1.89 | 3.8×10⁻¹¹ | 0.128 |
| IL6 | 1.67 | 4.8×10⁻¹⁰ | 0.116 |
| HLA-DRA | 1.56 | 1.2×10⁻⁸ | 0.109 |
| LTA4H | -1.78 | 1.2×10⁻⁸ | 0.093 |

#### **Microbiome Feature Importance**
| **Taxon** | **Fold Change (Cure vs Failure)** | **P-value** | **AUC Contribution** |
|-----------|-----------------------------|------------|-------------------|
| *Bacteroides fragilis* | +2.45 | 0.007 | 0.087 |
| *Prevotella copri* | +1.98 | 0.004 | 0.082 |
| *Faecalibacterium prausnitzii* | -3.21 | 0.003 | 0.079 |
| *Bifidobacterium bifidum* | +2.67 | 0.012 | 0.065 |
| *Escherichia/Shigella* | +1.92 | 0.018 | 0.058 |

#### **Genomic Feature Importance**
| **Mutation** | **Frequency in Success Cases** | **Adjusted P-value** | **AUC Contribution** |
|-------------|------------------------------|---------------------|-------------------|
| rpsL K43R | 24% | 0.025 | 0.076 |
| katG mutations (overall) | 58% | 0.042 | 0.072 |
| rpoB mutations (overall) | 67% | 0.031 | 0.069 |
| inhA promoter mutations | 34% | 0.089 | 0.051 |
| embB mutations | 29% | 0.056 | 0.048 |

### **Appendix B: Methodological Details**

#### **Multi-Omics Integration Pipeline**
1. Quality control and filtration
2. Normalization and transformation
3. Feature selection (variance >95th percentile)
4. Missing value imputation (KNN, k=5)
5. DIABLO parameter optimization
6. Feature importance ranking

#### **Machine Learning Implementation**
- **XGBoost hyperparameter optimization**: eta=0.1, max_depth=6, subsample=0.8
- **Random Forest**: n_estimators=500, max_features='sqrt'
- **SVM**: RBF kernel, C=1.0, gamma='scale'
- **Ensemble stacking**: GLM meta-learner with class probabilities

### **Appendix C: External Validation Results**

#### **Cross-Site Validation Performance**
| **Site** | **AUC (95% CI)** | **Sensitivity** | **Specificity** |
|----------|------------------|-----------------|-----------------|
| Cape Town (ZA) | 0.85 (0.79-0.91) | 87% | 79% |
| Lima (PE) | 0.88 (0.81-0.95) | 91% | 83% |
| Mumbai (IN) | 0.89 (0.84-0.94) | 90% | 85% |
| Phnom Penh (KH) | 0.84 (0.74-0.94) | 85% | 78% |
| Rio de Janeiro (BR) | 0.86 (0.78-0.94) | 88% | 80% |

#### **Economic Impact Projections**
- Current MDR-TB treatment cost: ~$15,000/patient
- Targeted intervention savings: ~$5,250/patient (35% reduction)
- Annual global savings: ~$46 million (based on 8,750 completely unaware treatment cases)

---

## **Funding and Acknowledgments**

This work was supported by:
- NIH-NIAID Global TB Research Program (grant #TB-2024-001)
- Wellcome Trust Human Microbiome Initiative (grant #HMI-2023-015)
- European Commission's Horizon Europe TB Programme (grant #EH-2024-TB-012)

We acknowledge the contributions of all MDR-TB patients and clinical teams at participating centers, and the technical assistance provided by the nf-core community and TB
